Cadin-1(10)-en-4beta-ol is a sesquiterpene alcohol that is often indexed in public chemistry databases under the closely related synonym cluster delta-cadinol or torreyol. The strongest evidence located for this AromaForge record is identity and occurrence data: live chemistry sources connect the archive name to the 1beta-cadin-4-en-10-ol synonym set, and local plus published oil profiles place it in hinoki and other wood-root oils. Direct standalone bioactivity evidence is limited; the available biological signals are mostly from whole essential oils where this constituent is one component rather than the isolated test article.
Chemical identity and composition
PubChem resolves delta-cadinol as CID 3084311 with formula C15H26O and lists 1beta-Cadin-4-en-10-ol and torreyol as synonyms. NIST's beta-Cadin-4-en-10-ol page reports the same formula and InChIKey family, supporting the archive record as part of the delta-cadinol or torreyol synonym cluster rather than as a separate well-studied constituent. In the archive, hinoki wood oil reports cadin-1(10)-en-4beta-ol at 6.76%, and a 2025 Laportea bulbifera root-oil paper reported cadin-4-en-10-ol at 4.7%.
Aroma and practical use
- Use the recorded woody, balsamic, earthy, cedar-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2025 Laportea bulbifera paper reported cadin-4-en-10-ol at 4.7% in the root essential oil, and that root oil showed bactericidal effects at 125 microL/mL against several tested bacteria; the result is useful mixture-level context but does not isolate the constituent's activity.
A 2025 Laportea bulbifera paper reported cadin-4-en-10-ol at 4.7% in the root essential oil, and that root oil showed bactericidal effects at 125 microL/mL against several tested bacteria; the result is useful mixture-level context but does not isolate the constituent's activity.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2017 Anthemis oils paper identified torreyol at 85.4% in Anthemis arvensis subsp. arvensis essential oil while the tested oils showed antimicrobial activity, reinforcing torreyol as a real natural-product identity and occurrence marker but not proving isolated activity.
A 2017 Anthemis oils paper identified torreyol at 85.4% in Anthemis arvensis subsp. arvensis essential oil while the tested oils showed antimicrobial activity, reinforcing torreyol as a real natural-product identity and occurrence marker but not proving isolated activity.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot assessed
Not assessed in the available record.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot assessed
Not assessed in the available record.
Penetration enhancementNot assessed
Not assessed in the available record.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA restriction, dermal limit, or human tolerability dataset was verified for isolated cadin-1(10)-en-4beta-ol in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the located activity signals come from whole-oil studies, archive copy should avoid antimicrobial or anti-inflammatory claims for the isolated constituent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Direct isolated pharmacology for cadin-1(10)-en-4beta-ol was sparse in the reviewed public literature.
- The identity literature overlaps substantially with delta-cadinol or torreyol naming, so some source sets are alias-based rather than dedicated to the archive spelling.
- Constituent-specific dermal, inhalation, reproductive, and long-term toxicology data were not verified in this pass.
- A c6 verification search (2026-07-13) for cadinol/torreyol RIFM or IFRA dermal data found only general QRA/DST methodology discussion, no compound-specific limit; the prior unsourced 20% dermal_limit_pct and sensitizing:true were corrected to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.